Megan Sanders, Chief Executive Officer at Thoracic Oncology Group of Australasia, shared on LinkedIn:
“The newly released Australian Medical Research and Innovation Strategy 2026–2031 and Priorities 2026–2028 offer some interesting signals about the future direction of Australian medical research funding.
My reading is that we may see a stronger emphasis on research that demonstrates not only what works, but how evidence can be translated into routine healthcare, at scale and with measurable benefits.
Several themes stand out.
- Implementation and health systems research
There is considerable emphasis on embedding research within health services, evaluating models of care and ensuring successful interventions can be implemented and sustained. This could create more opportunities for pragmatic trials, implementation science and health services research. - Genomics, AI and digital health
Multiomics-informed healthcare, artificial intelligence and integrated digital health systems are explicit priorities. Importantly, the emphasis extends beyond technology development to clinical validation, implementation and demonstrating improvements in patient care. - Clinical trials that address healthcare needs
Innovative trial designs, shared infrastructure and decentralised approaches are identified as important enablers. We may see increasing emphasis on trials that address evidence gaps in clinical practice, health technology assessment and prevention, alongside traditional therapeutic research. - Connected research infrastructure
The Strategy recognises the importance of interoperable data, coordinated research infrastructure and learning health systems. This could strengthen opportunities for research using clinical quality registries, real-world evidence and linked datasets to evaluate and improve care. - Workforce capability and sustainability
There is recognition that translating research into practice requires a skilled and sustainable workforce, including researchers embedded within health services. Research evaluating new workforce models and more efficient healthcare delivery may become increasingly attractive.
As a cooperative clinical trials group working across Australia and New Zealand, TOGA is well positioned to contribute to this direction. Our national network and experience in developing and conducting multicentre clinical trials provide a strong foundation for research that is relevant to clinical practice, applicable across different healthcare settings and capable of informing improvements in care.
Watching to see how these strategic priorities translate into future MRFF grant opportunities.”
You can also read: